Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America

Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KxY4EqD
via IFTTT